
Loading, please wait...

Loading, please wait...

Hepatocellular carcinoma (HCC) remains a significant challenge for clinicians because of its high molecular heterogeneity. Consequently, precise diagnosis and effective treatment strategies are often difficult to implement. Recent evidence highlights how lactate metabolism significantly influences tumor progression. In a groundbreaking study, Li et al. developed an interaction network using lactate metabolism HCC subtypes to create a robust stratification framework. This new approach offers a deeper understanding of how metabolic pathways drive cancer growth.
The researchers used consensus clustering to identify four distinct molecular subtypes of HCC. Among these, Cluster2 stood out as particularly significant. Patients in this group exhibited the worst overall prognosis. Furthermore, they showed an adverse response to immune checkpoint inhibitors (ICIs). This suggests that specific metabolic profiles can predict how well a patient will respond to modern immunotherapy. By validating these findings in independent cohorts, the study provides a reliable foundation for clinical decision-making.
An intriguing aspect of this research is the link between metabolism and the tumor microbiome. The study found that Cluster2 had the lowest beta-diversity in its microbial community. Additionally, there was a significantly higher abundance of the Streptomyces and Pseudoxanthomonas genera. These microbial changes were closely associated with the immune microenvironment. Therefore, the intratumoral microbiome may act as a critical player in the metabolic reprogramming of liver cancer cells.
To make these findings clinically actionable, the team identified a 5-gene signature using LASSO regression. This tool predicts survival across multiple HCC cohorts with high accuracy. Because the signature targets the specific vulnerabilities of the Cluster2 subtype, it could revolutionize personalized therapy. Clinicians can now potentially use this metabolic network-driven system to stratify patients more effectively. Ultimately, this leads to better-informed treatment choices and improved patient outcomes.
Lactate metabolism is a key driver of the tumor microenvironment. It promotes immune evasion and fuels cancer cell proliferation, making it a valuable target for both diagnosis and therapy.
Cluster2 is characterized by the poorest prognosis and resistance to immunotherapy. It also features a unique intratumoral microbiome composition, specifically showing higher levels of certain bacteria like Streptomyces.
The 5-gene signature serves as a prognostic tool. It allows doctors to predict survival outcomes and identify patients who might not respond well to standard treatments, facilitating more personalized care.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Li S et al. Lactate metabolism-related interaction perturbation network enables robust stratification of hepatocellular carcinoma. Discov Oncol. 2026 Feb 14. doi: 10.1007/s12672-026-04613-0. PMID: 41689750.
Llovet JM et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151-72.
Vaupel P, Multhoff G. Lactate in cancer biology: A journey from an end product of glycolysis to a tumor-promoting factor. Gene. 2021;799:145828.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A new study identifies four HCC subtypes based on lactate metabolism, offering a 5-gene signature to predict survival and guide personalized immunotherapy....
6 months ago

Emergency department overcrowding threatens patient safety and increases staff burnout. Adapting a staff-led vertical flow model with nurse-driven triage protocols in rural hospitals successfully decreases patient length of stay and reduces rates of patients leaving without being seen.
Today

A randomized double-blind non-inferiority trial shows haloperidol-ondansetron is non-inferior to dexamethasone-ondansetron for PONV prophylaxis after laparoscopic gynecological surgery, offering a safe, effective steroid-sparing alternative with reduced early postoperative pain.
Today

Following the admission of Union Health Minister JP Nadda to AIIMS Delhi for acute uneasiness, clinical teams utilized diagnostic coronary angiography and inpatient observation. This clinical review outlines acute triage pathways, procedural protocols, post-procedure observation, and long-term risk management.
Today

A comprehensive analysis of 2,764 trauma registry patients reveals that occupant ejection during rollover crashes increases mortality fourfold. Nonuse of seatbelts escalates ejection risk tenfold, highlighting the urgent need for strict restraint compliance and targeted road-safety interventions.
Today

Diabetic kidney disease remains a major cause of renal failure despite renin-angiotensin system blockade. Learn how combining SGLT2 inhibitors, nonsteroidal MRAs, GLP-1 receptor agonists, and novel aldosterone synthase or endothelin inhibitors addresses residual cardiorenal risk.
Today